Number of Current Board & Advisor Roles 16
Number of Founded Organizations 1
  • Investor Type  Investment Partner

James Topper joined Frazier Healthcare in 2003 as a Venture Partner and became a General Partner in 2005.James Topper is a member of the firm's Biopharma Venture team.

Since joining Frazier Healthcare, James Topper has led multiple Biopharma Venture investments including Incline Therapeutics that was acquired by The Medicines Company for up

to $390 million, Calistoga Pharmaceuticals that was acquired by Gilead in April 2011 for total consideration of up to $600 million, Alnara Pharmaceuticals that was acquired by Eli Lilly for total consideration of up to $390 million, and Cotherix (Nasdaq CTRX) that was acquired by Actelion for $420 million and a successful PIPE investment in Threshold Pharmaceuticals (Nasdaq THLD).

James Topper currently serves on the boards of Amicus Therapeutics (Nasdaq FOLD), Atterocor, Semnur Pharmaceuticals, Portola Pharmaceuticals, Anaptys Biosciences, Allena Pharmaceuticals, Alcresta and Rempex Pharmaceuticals.

In 2011 James Topper was named to the Forbes Midas list representing the top 100 venture capitalists.

Number of Current Jobs 3
Number of Past Jobs 7
James Topper has 3 current jobs including General Partner at Frazier Healthcare Partners, Co-Founder at Calistoga Pharmaceuticals, and Managing General Partner at Frazier Healthcare Partners. Additionally, James Topper has had 7 past jobs including Team Member at Harvard Medical School.
Organization Name  
Title At Company  
Start Date  
End Date  
Harvard Medical School
Team Member19971998
COR
Vice President of Biology
Palo Alto VA Hospital
Cardiology Consultant
Stanford University School of Medicine
Team Member
Frazier Healthcare Partners
Venture Partner2003
COR Therapeutics Inc
Head of th Cardiovascular Research & Development
Millennium Pharmaceuticals
Head of th Cardiovascular Research & Development
Number of Current Board & Advisor Roles 16
James Topper holds 16 board and advisor roles including Board Member at Enlaza Therapeutics, Board Member at Entasis Therapeutics, and Board Member at Lassen Therapeutics.